Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21937370 | 0.85 | ALDH1A1 (0.49) | ALDH1A1GAAKDM1ATLR8BRD4 | |
| Hydrochloric Acid SCHEMBL5526375 | 0.84 | LMNA (0.42) | ALDH1A1GAAMAOA | |
| Hydrochloric Acid SCHEMBL5526369 | 0.84 | LMNA (0.42) | ALDH1A1GAAMAOA | |
| SCHEMBL20804977 | 0.83 | FFAR1 (0.46) | ALDH1A1GAATLR8 | |
| SCHEMBL10289878 | 0.83 | ALDH1A1 (0.48) | ALDH1A1GAAKDM1AGRM2TLR8 | |
| SCHEMBL765840 | 0.81 | ALDH1A1 (0.42) | ALDH1A1GAAKDM1AGRM2TLR8 | |
| SCHEMBL12388688 | 0.81 | FFAR1 (0.44) | ALDH1A1GAATLR8MAOAMAOB | |
| SCHEMBL15057756 | 0.81 | AAK1 (0.42) | ALDH1A1GAAKDM1AGRM2TLR8 | |
| SCHEMBL20189994 | 0.80 | ALDH1A1 (0.41) | ALDH1A1GAAKDM1AGRM2TLR8 | |
| SCHEMBL10314839 | 0.80 | L3MBTL1 (0.52) | ALDH1A1GAAGRM2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885GAA 184/4885KDM1A 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.